title: [Generalization of Helicobacter pylori eradication therapy and its future in Japan].
abstract: After official acceptance of eradication therapy for Helicobacter pylori infected peptic ulcer disease in 2000, this treatment has been generalized as ulcer therapy in Japan. In 2003 the consensus statement of the Japanese Society for Helicobacter Research (JSHR) for Helicobacter pylori infection was presented. According to this statement MALT lymphoma was recommended to treat H. pylori infection because of the efficacy of its out come. Atrophic gastritis was also advised to treat H. pylori infection for the purpose of preventing gastric cancer development. The extra alimentary disease such as idiopathic thrombocytopenic purpura was still under evaluation. In diagnostic method the importance of drug susceptibility test is rising because of the increase of drug resistant H. pylori strain in Japan. The false positive case of urea breath test, the accuracy of new Japanese original serology tests and the stool antigen test are also under investigation. The standard regimen of H. pylori eradication therapy in Japan is proton pomp inhibitor (PPI) + amoxicilin (AMPC) + clarithromycin (CAM). The problem of this regimen is the decrease of eradication rate. The reason of this trend might be increase of CAM resistant strain. JSHR recommended a rescue regimen as PPI + AMPC + metronidazole for the patient whose first eradication therapy was unsuccessful result. The eradication of this second line regimen was reported as about 90%.
authors.affiliation: The Third Department of Internal Medicine, Kyorin University School of Medicine.
authors.forename: Shin'ichi
authors.initials: S
authors.lastname: Takahashi
authors.forename: Kengo
authors.initials: K
authors.lastname: Tokunaga
authors.forename: Akifumi
authors.initials: A
authors.lastname: Tanaka
mesh_terms: D000658:Amoxicillin / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D017291:Clarithromycin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy; D010437:Peptic Ulcer / Q000188:drug therapy; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy
chemical_list: D000900:Anti-Bacterial Agents; D000658:Amoxicillin; D017291:Clarithromycin